No Boundaries for Toxicology in Clinical Medicine: One Health, One Society and One Planet for All of Us

The concept of One Health is not new; it can be traced back for at least two hundred years [...].

emergencies such as COVID-19 pandemic, monkeypox, Ebola outbreaks, and continued threats of other zoonotic diseases, food safety, antimicrobial resistance, as well as ecosystem and climate negative alterations, the heads of the Quadripartite organizations working on One Health (i.e., World Health Organization (WHO), Food and Agriculture Organization of the United Nations (FAO), United Nations Environment Programme (UNEP) and the World Organisation for Animal Health (WOAH)), at their first annual meeting, issued an unprecedented call for an accelerated and prioritized global political action focusing on One Health as a unique solution to face future treats [6]. tious diseases, neglected tropical diseases, antimicrobial resistance, climate change, ronmental health and pollution, and food safety, among others, has been steadily in ing. Already in March 2023, due to the health emergencies such as COVID-19 pand monkeypox, Ebola outbreaks, and continued threats of other zoonotic diseases, safety, antimicrobial resistance, as well as ecosystem and climate negative alteration heads of the Quadripartite organizations working on One Health (i.e., World Healt ganization (WHO), Food and Agriculture Organization of the United Nations (F United Nations Environment Programme (UNEP) and the World Organisation for mal Health (WOAH)), at their first annual meeting, issued an unprecedented call f accelerated and prioritized global political action focusing on One Health as a uniqu lution to face future treats [6]. Historically focused on zoonoses [7], the concept of One Health has paid less tion to animal, human, and environmental exposure to toxics. The application of th Health concept to toxicology and pharmacology is obvious, as these specialists on biotics work in synergy with other medical and nonmedical professionals. Despi variability in the dose response and toxicokinetics between domestic and wildlife ani plants, and humans, biochemical and physiological systems are highly conserved a species, meaning that the toxic effects can be common to them [8]. This suggests tha Historically focused on zoonoses [7], the concept of One Health has paid less attention to animal, human, and environmental exposure to toxics. The application of the One Health concept to toxicology and pharmacology is obvious, as these specialists on xenobiotics work in synergy with other medical and nonmedical professionals. Despite the variability in the dose response and toxicokinetics between domestic and wildlife animals, plants, and humans, biochemical and physiological systems are highly conserved among species, meaning that the toxic effects can be common to them [8]. This suggests that, if a specific group of species is at risk, other groups of species can be also affected. Therefore, the term "One Toxicology" emerged to encourage more efficient collaborative research, data, and knowledge sharing, as well as stewardship actions among groups of toxicologists [8]. Some examples of One Health toxicology research include studies on the effects of pollution on aquatic ecosystems, the impact of pesticides on honeybee populations and other pollinators, and the health risks associated with exposure to toxics trafficked via foods. In addition, some tragedies highlight the concept of One Health applied to toxicology. The Minamata Bay (Japan) tragedy in the 1950s, due to mercury exposure, is one example since it illustrated how an industrial pollutant can be biomagnified in an aquatic ecosystem from marine microorganisms up the food chain, and how the poisoned and dead floating fish, predators, and scavengers should have served as sentinels and alarm for this outbreak of environmental illness, before its effects were felt by the human population [9]. The great London fog, which blanketed the British capital for five days in December 1952, caused more than 12,000 human deaths [10]. The etiology was only discovered almost one year later, but respiratory-related sudden death in cattle was indicative of the air pollution problem before it was recognized as the cause of human deaths [11]. Nevertheless, animals can only act as sentinels for human beings (as occurred in the case of canaries used to warn coal miners of methane or carbon monoxide levels) if their existence is maintained. Another good example was described in Rachel Carson's book Silent Spring, reporting the tragedy of silenced birds due to biomagnification and exposure to the organochlorine insecticide dichlorodiphenyltrichloroethane (DDT) [12]. What is unquestionable is that thousands of chemicals are produced and disseminated through manufacturing, pharmacological treatments, pest control, and food industries, to name few examples. This means that there is an interdependence between humans and the ecosystems, highlighting that human health is ultimately dependent on the health of our planet [13,14]. The European Union developed the REACH Regulation (focused on four processes: the registration, evaluation, authorization, and restriction of chemicals) to address the safety of chemicals already in the marketplace, aiming to protect human health and the environment. The REACH Regulation places responsibility on the industry to manage the risks from chemicals and to provide safety information on the substances. It also requests the progressive substitution of the most dangerous chemicals (referred to as "substances of very high concern") when suitable alternatives have been identified. In the US, the Toxics Substances Control Act (TSCA) Reform offers similar approaches.
In the toxicology-pharmacology areas, some recent findings published in the Journal of Clinical Medicine, with an intersection with other scientific areas, are worth mentioning. The everyday appearance of new psychoactive substances (NPS) and the consequent morbidity and mortality associated with their consumption is a highly recognized problem [15]. Piperazine derivatives are among the most studied psychoactive compounds in this group of designer drugs, especially as alternatives to the recreational use of 3,4methylenedioxymethamphetamine and other amphetamine derivatives. However, for the success of effective treatments, analytical techniques are needed, since laboratories do not have or include toxicological analysis in their portfolio, rendering diagnosis mostly based on clinical history. Welz et al., in complementary studies [16,17], developed two liquid chromatographic techniques using a diode-array detector (LC-DAD) and a mass spectrometer (LC-MS) for the rapid qualitative and quantitative analysis of piperazine derivatives in serum and urine. Such techniques represent an important evolution to facilitate the clinical diagnosis of the intoxications by these substances. Additionally, on the subject of NPS, Poyatos and colleagues [18], following the PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines, presented for the first time a systematic review on the origins, chemistry, pharmacodynamics, and pharmacokinetics of cathinones such as mephedrone, methylone, and diethylpropion. It was evidenced that these psychoactives induce a range of desirable and reinforcing effects that may, to some extent, result in abuse potential. However, psychoactives, even illicit ones, can also possess useful biological activities if their dose is correctly titrated, as I recently highlighted in an Editorial of a new journal of the Multidisciplinary Digital Publishing Institute (MDPI) portfolio [19]. Following this desideratum, toxicological risks and clinical benefits of ayahuasca intake were fully reviewed, exploring the direct link between decoction doses and corresponding blood concentrations and their physiological and psychological effects in humans [20]. In this context of the abuse of psychoactives, Daniel Dacosta-Sánchez and colleagues [21] took a step forward by exploring the usefulness of electronic health records (EHRs) and Real World Data to uncover the factors that may explain the dissatisfaction with therapy, increasing the risk of drop-out in patients with opioid and cannabis use disorder (SUD) [22,23]. Particularly, their data complement the evidence previously obtained through observational studies and clinical trials by having access to a large sample size (n = 2458 inpatients).
As highlighted before for several pharmacological drugs with abuse potential [24][25][26][27][28][29][30][31][32], the study of drug pharmacokinetics and pharmacodynamics represents a powerful approach to prevent adverse effects such as dependence by understanding the consequences of the polymorphic metabolism and implementing the most suitable doses and posology. In this sense, a crossover, double-blind, placebo-controlled, randomized clinical trial to characterize the pharmacokinetics and pharmacodynamics of carisoprodol and its main active metabolite (i.e., meprobamate) was developed with the aim of uncovering the possible factors that may contribute to carisoprodol's dependence and abuse [33,34]. Indeed, carisoprodol is a centrally acting muscle relaxant, but it has been used for non-medical reasons, including diversion and trafficking [35]. The most relevant findings were the implications of CYP2C19 genotype's polymorphism in the metabolism of carisoprodol, and the lack of evidence of withdrawal symptoms and a reduced risk of dependence [33,34]. In a different field, a protocol following the STROBE guideline was proposed to study the pharmacokinetic properties of piperacillin/tazobactam and hydrocortisone, as well as the concentrations of inflammatory markers and adrenal steroids during the treatment of community-acquired pneumonia [36]. It is expected that a personalized therapeutic regimen and improved treatment outcomes will be possible due to high inter-and intraindividual variability in pharmacokinetic parameters.
Discussing toxicology in a unifying approach to balance and optimize the health of people, animals, and the environment is needed. By taking a One Health approach to toxicology, researchers can gain a more complete understanding of the impacts of toxic substances on the health of multiple species, as well as the ecological and societal implications of these impacts, and clues to reach a greener chemistry. This can help inform policy decisions concerning the regulation and management of toxic substances, with the goal of promoting the health and well-being of all living beings. Innovative research directly related to toxicology (e.g., ecotoxicology, education in toxicology, food toxicology, environmental toxicology, analytical toxicology, clinical toxicology, forensic toxicology, veterinary toxicology, occupational toxicology, toxinology and regulatory toxicology), but also at the interface of biomedical, biochemistry and environmental Sciences (e.g., medicine, nutrition, veterinary medicine, pharmaceutical sciences, and forensic sciences), with crosscutting issues within the Sustainable Development Goals, is welcome. Real world data and evidence will further improve the translational impact, enabling the development of ecological and needs-oriented research, and to identify the specificities, risk, and resilience factors of the individuals to the toxic insults on health. Finally, multidisciplinary approaches involve the study of toxicological interactions and implications to One Health, biosorbents and environment, food microbiology, chemical compounds and therapeutic implications, drug repurposing, biomarkers, cancer studies, the development of analytical methodologies, and the analysis of real-world data and evidence for a better understanding of the diseases from a global picture point of view.

Conflicts of Interest:
The author declares no conflict of interest.